Dysfunction of nerve growth factor (NGF) and its high (TrkA) and low (p75 NTR ) affinity receptors has been suggested to underlie the selective degeneration of the nucleus basalis (NB) cholinergic cortical projection neurons in end stage Alzheimer disease (AD). Whether the NGF system is dysfunctional during the prodromal stages of AD has only recently been evaluated. Surprisingly, the number of choline acetyltransferase-containing neurons remains stable despite a significant reduction in NGF receptor-positive cells in people with mild cognitive impairment (MCI), suggesting a phenotypic NGF receptor downregulation but not a frank loss of NB neurons during prodromal AD. Moreover, there is a loss of cortical TrkA in the face of stable p75 NTR and increased proNGF levels, the precursor molecule of mature NGF, in early AD. Depending upon the cellular context these changes may result in increased pro-apoptotic signaling, cell survival, or a defect in retrograde transport mechanisms. Alterations in NGF and its receptors within the cholinotrophic NB system in early AD suggest that NGF-mediated cell signaling is required for the longterm survival of these neurons. Therapeutic neurotrophic intervention might delay or prevent NB neuron degeneration and preserve cholinergic cortical function during prodromal AD.
INTRODUCTION
Cholinergic basal forebrain (CBF) neurons within the nucleus basalis (NB) provide the major source of cholinergic innervation to the cerebral cortex (1, 2) and play a key role in memory and attention function (3) (4) (5) (6) (7) . These cortical projection neurons undergo extensive degeneration in late stage Alzheimer disease (AD), which correlates with clinical severity and disease duration (8) (9) (10) (11) (12) (13) . CBF neurons require nerve growth factor (NGF) for their survival and biologic activity (14) (15) (16) . Cellular responses to NGF are elicited through binding and activation of its cognate receptors, TrkA and p75
NTR (14, 17, 18) , which are produced within CBF neurons and anterogradely transported to the cortex and hippocampus (19) . Approximately 20 years ago, it was hypothesized that degeneration of CBF neurons was due to a loss of neurotrophic support from target sites that produce NGF in AD (20) (21) (22) . These observations were based solely upon studies that examined autopsy material harvested from late-stage AD patients. To better understand the neurobiologic mechanism(s) that underlie the onset of this cholinotrophic deficit and its relation to cognitive impairment, we examined postmortem brain tissue derived from the Religious Orders Study (ROS), a longitudinal clinical pathologic study of aging and dementia in retired Catholic clergy (23) (24) (25) (26) (27) (28) . Each ROS participant received an annual detailed clinical evaluation, including a battery of tests for function in five cognitive domains (orientation, attention, memory, language, and perception) and agreed to brain autopsy and neuropathologic analysis. These individuals were categorized as having no cognitive impairment (NCI), mild cognitive impairment (MCI), or AD. In this review, we describe the findings generated from our clinical pathologic investigations of the cholinotrophic basal forebrain system in the ROS cohort. These studies have provided unique insights into the role that NGF receptor impairment plays in CBF neuronal dysfunction during the prodromal stages of AD.
NGF AND THE SURVIVAL OF CHOLINERGIC BASAL FOREBRAIN NEURONS
Several lines of evidence support a role for NGF in the survival of cholinergic NB neurons. In vitro studies using dissociated rat NB cultures (29, 30) or organotypic NB slices (31) showed that NGF treatments prevented the degeneration of cholinergic neurons observed in untreated preparations. Likewise, the atrophy and loss of cholinergic NB neurons in vivo following experimental neocortical infarction in monkeys (32) or excitotoxic neocortical lesions in rats (33) were reversed with exogenous NGF treatment. These results are similar to those demonstrating that infusion of NGF can prevent septal cholinergic neuron death following septohippocampal axotomy (34) (35) (36) . Finally, transgenic mice that express anti-NGF antibodies in adulthood display an agedependent loss of CBF neurons (37, 38) .
Cholinergic NB neurons express 2 NGF receptors, the pan-neurotrophin receptor p75
NTR and the NGF-specific receptor tyrosine kinase TrkA, which mediate the binding, internalization, and retrograde transport of target-derived NGF from the cortex to NB soma (14, 18, 19, 39) . p75 NTR is a member of the tumor necrosis factor receptor family and binds NGF with relatively low affinity (K d = 10 29 ) (40, 41). The p75 NTR receptor lacks intrinsic catalytic activity but interacts with cytosolic adaptor proteins to activate downstream signaling molecules including c-jun N-terminal kinase (JNK) and nuclear factor kB (NFkB) (42) (43) (44) . Activation of these pathways through p75 NTR in vitro can elicit either a proor anti-apoptotic signal that most likely depends on the cellular milieu (e.g. cell type, presence or absence of specific binding partners [ (44, 45] ). TrkA is a receptor tyrosine kinase that binds NGF with relatively high affinity (K d = 10
211
) when coexpressed with p75 NTR (41, 46, 47) . Upon binding of NGF to TrkA, the receptor activates signal transduction cascades, including the mitogen-activated protein kinase (MAPK)/-cAMP regulatory element binding protein (CREB), phosphatidylinositol 3 kinase (PI3K), and phospholipase C-g (PLCg) pathways, that promote the survival and cholinergic phenotype of NB neurons through the activation of transcription factors that alter gene expression (15, 16, 48, 49) .
Schwaab et al first presented evidence suggesting that retrograde transport of NGF within cholinergic NB neurons was critical for its neurotrophic effects by demonstrating retrogradely labeled NB perikarya following injection of 125 I-labeled NGF into the rat neocortex (50) . Furthermore, intraventricular administration of either radiolabeled or exogenous NGF followed by emulsion autoradiography or immunohistochemistry of rat brain tissue sections verified the retrograde transport of NGF, bilaterally, to NB perikarya (51) . The mechanism by which NGF retrograde transport proceeds and culminates in cell survival has not been fully elucidated, but a series of observations indicate that NGF-bound TrkA complexes are internalized as specialized ''signaling endosomes'' (52-54) by a process that involves dynamin (55) and PI3K (56, 57) . These signaling endosomes appear to be transported in the minus direction along microtubules, as dynein inhibition or microtubule disassembly blocks the retrograde transport of both NGF and Trk receptors (57, 58) . Significantly, application of NGF to distal axons in compartmentalized sympathetic neurons induced CREB phosphorylation in cell bodies in an endocytosis-dependent manner (59) . CREB-mediated gene expression was both necessary and sufficient for NGF-dependent survival in this paradigm (60) , suggesting that the formation and retrograde transport of signaling endosomes is required for nuclear responses to NGF and critical for cholinergic cell survival.
NGF RECEPTOR ALTERATIONS IN MCI AND AD
The cholinotrophic phenotype of NB neurons is altered during the prodromal and earliest stages of AD. Quantitative unbiased stereologic counting studies revealed that the number of NB perikarya expressing either choline acetyltransferase (ChAT, the synthetic enzyme for acetylcholine, or ACh) or the vesicular ACh transporter (VAChT) was unchanged in subjects clinically diagnosed with MCI or mild AD compared with those diagnosed as NCI ( Fig. 1) (25) . Moreover, other studies demonstrated that ChAT activity in NB cortical projection sites was stable in the early stages of AD or increased in the superior frontal cortex of MCI subjects (61) . Taken together, these observations suggest that basocortical cholinergic tone is preserved in MCI and early AD, supporting the notion that cholinergic NB neurotransmission dysfunction is a late-stage event in AD (10, 11, 62) . On the other hand, stereologic counting studies revealed that the number of NB perikarya expressing either TrkA or p75 NTR was reduced ;50% in MCI and mild AD compared with NCI (Figs. 1 and 2) (27, 28). Intriguingly, there was a significant positive correlation between the number of TrkA-immunoreactive NB neurons and performance on the Boston Naming Test and Global Cognitive Test measures of cognitive function in the ROS individuals examined (27) . Similarly, the number of p75 NTRimmunoreactive NB neurons was significantly correlated with performance on the Mini-Mental State Examination (MMSE) and the Global Cognitive Test (28) . These chemoanatomic stereologic studies indicate that many cholinergic NB neurons undergo a phenotypic silencing of NGF receptor expression in the absence of frank cell loss or cholinergic deficits during the early stages of AD that correlates with cognitive impairment. The more pronounced early defects in NGF receptor expression may be a precursor to the eventual extensive cell loss seen within the CBF in end-stage AD.
NGF receptors are synthesized within NB perikarya and anterogradely transported to the cortex. Therefore, we performed quantitative immunoblotting experiments to measure TrkA and p75 NTR protein levels in five NB cortical projection sites (anterior cingulate, superior frontal, superior temporal, inferior parietal, and visual cortex) during the progression of AD (Fig. 3A) (24) . Whereas cortical levels of p75 NTR protein were stable across the diagnostic groups, TrkA protein in the cortex was reduced ;50% in mild AD compared with NCI and MCI subjects (Fig. 3B) . Furthermore, cortical TrkA levels were positively correlated with MMSE performance ( Fig. 4) (24) . As TrkA signaling is associated with neuronal survival (15, 16, 48, 49) , this specific reduction of cortical TrkA receptor protein may play a key role in the frank loss of cholinergic NB neurons observed in later stages of AD (11, 13) .
MECHANISMS OF NGF RECEPTOR ALTERATIONS IN MCI AND AD
The mechanisms underlying TrkA protein reduction in NB perikarya in MCI and its projection sites in early AD are unclear. However, TrkA gene expression is under positive feedback from NGF signaling (63, 64) , and this pathway may be disrupted in AD by diminished retrograde transport of cortical NGF to cholinotrophic NB consumer neurons (65, 66) . In support of this hypothesis, NGF levels are stable (67, 68) or increased (66, 69) in the cortex, whereas NGF levels are decreased in NB neurons in late-stage AD (65, 66) . Notably, defective retrograde transport of NGF within cholinergic projection neurons was recently reported in a transgenic mouse model of Down syndrome, a congenital neurodegenerative disorder that mimics the neuropathology of AD (70) . In aged rats, these neurons exhibited a pronounced reduction in NGF retrograde transport, reduced TrkA protein expression, and severe atrophy (71, 72) . Defective NGF retrograde transport may therefore underlie the reductions in NB trkA gene (73, 74) and protein (27, 75) expression observed in single NB neurons in MCI and early AD, leading ultimately to reduced TrkA protein in cortical projection sites (24, 75) and further perturbations in NGF signaling within the NB. This putative ''off trk'' cycle of deficient NGF signaling may contribute to the selective degeneration of cholinergic NB neurons and deficits in cortical cholinergic tone observed in late-stage AD (6, (8) (9) (10) (11) (12) (13) 51) .
The stability of p75 NTR protein expression levels observed across clinical diagnosis in the cortical regions examined was surprising in light of our stereologic data showing that NB perikarya expressing p75 NTR were reduced in both MCI (38%) and mild AD (43%) relative to NCI (Figs. 1  and 2 ). Moreover, cortical p75 NTR levels remain stable even in severe AD despite a dramatic reduction of p75 NTR -immunopositive neurons and fibers in the NB in late-stage AD (11, 76) . However, gene expression profiling studies of single cholinergic NB neurons revealed that p75 NTR mRNA levels were unchanged in end-stage AD compared with age-matched controls (74) . Hence, the persistence of p75 NTR protein expression in the cortex in MCI and AD subjects may reflect a compensatory response in remaining p75 NTR -containing NB neurons to stabilize cortical receptor levels.
FUNCTIONAL CONSEQUENCES OF NGF RECEPTOR ALTERATIONS IN MCI AND AD
TrkA receptor reductions in basocortical projections would presumably result in a loss of TrkA-mediated NGF signaling through downstream effector molecules such as MAPK and PI3K that are related to NB cell survival (15, 16, 48, 49) . TrkA activation of the MAPK family members, extracellular signalrelated kinases 1 and 2 (ERK1/2), results in the translocation of these kinases to the nucleus (15, 16, 48, 49) . One of the principal downstream nuclear targets of ERK1/2 is the transcription factor CREB. CREB-mediated transcription plays an important role in neuronal survival (59, 60, 77, 78) , likely via an anti-apoptotic mechanism involving the upregulation of bcl-2 gene expression (60, 79) . Significantly, disruption of TrkA kinase activity following NGF treatment resulted in defects in nuclear CREB activation in sympathetic neurons (59) . In addition, experiments using compartmentalized dorsal root sensory neurons revealed that another MAPK member, ERK5, activates CREB and promotes neuronal survival when NGF is applied to distal axons (80) .
A role for PI3K in TrkA-mediated neuronal survival is supported by observations that the PI3K inhibitors wortmannin and LY294002 induce apoptosis in NGF-protected PC12 cells and sympathetic neurons (81) (82) (83) . The principal downstream mediator of PI3K is Akt kinase, which reportedly promotes cell survival through a phosphorylation cascade that prevents the insertion of proapoptotic Bax proteins into the mitochondrial membrane, an event that breaks down the membrane potential and promotes the release of cytochrome c and apoptotic signaling (84) (85) (86) (87) (88) . In addition, in vitro and in vivo activation of PI3K following NGF exposure is required for TrkA internalization and retrograde transport (56, 57, 89) , providing a potential mechanistic link between reduced cortical TrkA and diminished pro-survival signaling in CBF neurons.
The stability of cortical p75 NTR protein despite a loss of cortical TrkA protein in AD may result in a relative increase in p75 NTR -mediated NGF signaling in cholinergic NB neurons. p75 NTR has traditionally been thought to serve a facilitatory role in NGF signaling by producing high-affinity NGF binding sites and increased TrkA responsiveness to NGF (41, 46, 90) . However, biochemical findings indicate that p75 NTR possesses complex autonomous signaling capabilities in response to NGF that, paradoxically, regulate both cell death or cell survival under different experimental conditions. NGF stimulation of p75 NTR in the absence of TrkA induces apoptosis in neuronal populations (91) (92) (93) (94) (95) (96) and mature oligodendrocytes (42, 97) . Furthermore, retroviral infection of mature p75 NTR -positive oligodendrocytes with trkA cDNA reverses NGF-induced apoptosis (97) , indicating that the coexpression of TrkA appears to suppress p75 NTR -mediated proapoptotic signaling. The mechanism for p75 NTR -mediated cell death is unclear, but activation of the JNK pathway has emerged as a primary carrier of the p75 NTR proapoptotic signal (42, 91, 93, 97, 98) . NGF binding to p75 NTR results in the phosphorylation and activation of JNK, which translocates to the nucleus to phosphorylate the transcription factor c-Jun (99) . Phosphorylated c-Jun-mediated transcription initiates a proapoptotic cascade involving the release of cytochrome c and caspase activation (44, (100) (101) (102) .
There is also intriguing evidence that p75 NTR -mediated apoptosis involves the activation of cell cycle regulatory molecules. In postmitotic, p75 NTR -positive retinal neurons, NGF-mediated apoptosis is preceded by a significant increase in mitotic figures and an upregulation of cyclin B2, which is typically active at the G2/M transition, and apoptosis can be prevented in a dose-dependent manner by the CDK1 cyclin B2-dependent kinase inhibitor roscovitine (103) . A link between the aberrant cell cycle reentry of postmitotic neurons and apoptosis has been established in several experimental paradigms (104) (105) (106) (107) , and the AD brain is characterized by neuronal expression of cell cycle regulatory proteins (108) (109) (110) and evidence for DNA replication (111) . More recently, we have demonstrated the presence of cell cycle proteins PCNA, cyclin D1, and cyclin B1 in NB neurons in MCI and mild AD (112) (Fig. 5) . Thus, increases in p75 NTR -mediated activity in the face of reduced TrkA signaling may contribute to NB neurodegeneration in AD by promoting unscheduled cell cycle reentry and apoptosis. Taken together, these data suggest that the ratio of TrkA to p75 NTR receptors may determine whether neurons survive or die when exposed to NGF. As such, the ;50% reduction in cortical TrkA at the onset of AD may signify a relative increase in pro-apoptotic p75 NTR signaling in cholinergic NB neurons.
PRO-NGF AND NUCLEUS BASALIS NEURON SURVIVAL
The physiologic consequences of TrkA and p75 NTR signaling may depend upon their interactions with the NGF precursor protein proNGF. Quantitative immunoblotting studies demonstrated that proNGF is the predominant form of NGF present in the cortex of aged intact humans (113) . ProNGF levels increase~40% to 60% in the inferior parietal cortex of subjects diagnosed with MCI or mild AD compared with NCI ( Fig. 6) (114) . This finding was intriguing given the previous demonstration that levels of total NGF (as detected by enzyme-linked immunosorbent assay, or ELISA) were unchanged in the cortex of these same individuals (67) . This discrepancy may be due to technical differences in the studies (e.g. immunoblotting vs ELISA) or may indicate that if levels of total NGF are unchanged, then the ratio of proNGF to mature NGF increases during disease progression. The biologic consequences of proNGF accumulation in the cortex during the prodromal stages of AD have yet to be determined. An emerging body of literature suggests that recombinant proNGF binds TrkA and promotes neuronal survival and neurite outgrowth similar to mature NGF but is approximately 5-fold less active than mature NGF (115, 116) . Although TrkA-mediated proNGF retrograde transport has not been demonstrated, proNGF accumulation in NB target sites may be due to reduced cortical TrkA levels and/or retrograde transport to cholinotrophic basal forebrain perikarya. Significantly, while TrkA levels in the cortex were positively associated with MMSE scores (24) , cortical proNGF levels were negatively correlated with MMSE performance (Fig. 4)  (114) . Thus, the concomitant reduction of TrkA and accumulation of proNGF in the cortex may be an early pathobiologic marker for the onset of AD.
In contrast, other studies indicate that increases in cortical proNGF may result in pro-apoptotic signaling through binding to the p75 NTR receptor. In support of this, a different form of recombinant proNGF was shown to bind p75 NTR with high affinity and promote neuronal apoptosis (117) . More recent data indicate that the pro-apoptotic effect(s) of p75 NTR -mediated proNGF signaling is(are) dependent on interactions between p75 NTR and the neurotensin receptor sortilin (118) . Sortilin binds the ''pro'' region of proNGF, and blocking this binding event precludes high-affinity binding of proNGF to p75 NTR . Moreover, sortilin expression is required for p75 NTR -mediated apoptosis following proNGF treatments (118) , suggesting that sortilin is a p75 NTR binding partner associated with its role in the initiation of cell death mechanisms (44, 45) . Intriguingly, preliminary findings suggest that cortical sortilin levels are increased in AD patients compared with normal controls (E. J. Mufson and A. Nykjaer, unpublished observations), potentially facilitating proNGF binding to p75 NTR triggering proapoptotic activity in the diseased brain. In Figure 7 , we diagram the potential scenarios for prosurvival (Fig. 7A) or pro-apoptotic (Fig. 7B ) signaling in cholinergic NB neurons as TrkA levels decline, p75
NTR levels remain unchanged, and proNGF levels rise in cortical projection sites during the progression of AD.
CHOLINOTROPHIC THERAPY FOR AD
The reciprocal correlations between reduced cortical TrkA and elevated proNGF levels with MMSE scores suggest that cholinotrophic abnormalities play a key role in cognitive impairment and may underlie the eventual demise of NB neurons and the extensive cholinergic deficits seen in the late stages of AD. Previous studies in nonhuman primates have shown that recombinant human NGF reverses both age-related and lesion-induced cholinergic neuronal degeneration and promotes cholinergic neurite sprouting (32, (119) (120) (121) (122) (123) (124) . In addition, exogenous NGF rescues age-related and cholinergic lesion-induced spatial memory deficits in rodents (125, 126) . Thus, restoration of NGF signaling may prove efficacious for the prevention of cognitive deficits resulting from NB dysfunction in AD. Along these lines, a Phase I clinical trial has begun wherein mild AD subjects receive grafts of autologous fibroblasts genetically modified to secrete human NGF (127) . Cells are implanted directly in the NB so this therapeutic strategy may bypass putative defects in the retrograde transport of NGF and may even restore TrkA expression in AD. To date, these patients have not shown any adverse affects from these NGF intraparenchymal injections, and early indications are that NGF therapy may even slow the course of the disease (128) . Alternatively, the ongoing development of TrkA-specific NGF peptidomimetics has provided the groundwork for another potential approach to improving prosurvival signaling in NB neurons in people during the early stages of AD (129) (130) (131) . Most recently, the in vivo efficacy of a selective, partial TrkA agonist has been demonstrated in cognitively impaired aged rats (132) . Intraventricular infusion of this ligand resulted in long-lasting cognitive improvement in spatial memory tasks, significantly higher density of cortical VAChT-positive fiber staining, and significantly increased cell size of VAChT-positive soma in the NB (132) . These data suggest that partial activation of TrkA can upregulate the cholinergic phenotype of the basocortical projection system and improve cognition in the absence of p75 NTR activation. Figure 8 summarizes our current findings dealing with the pathobiology of the cholinotrophic basocortical projection system during the progression of AD. The preservation of ChAT/VAChT-containing NB neurons in the face of reduced numbers of TrkA and p75 NTR -containing NB in MCI and mild AD indicates that there is not a frank loss of cholinergic perikarya, per se, but a phenotypic downregulation of NGF receptor proteins in these neurons that may compromise neurotrophic support early in the disease process. Interestingly, the reduction of NGF receptors in NB neurons seen in MCI also occurs in the presence of normal or elevated cortical ChAT activity, suggesting that compensatory cellular mechanisms attempt to maintain the cholinergic function of these cells during the prodromal stages of AD. The stability of cortical TrkA and p75 NTR protein levels in MCI subjects despite the loss of these receptors within the NB may represent yet another compensatory response whereby NGF receptor protein is upregulated in remaining NB neurons and anterogradely transported to the cortex to preserve targetderived NGF signaling and cholinergic tone. As such, the selective loss of cortical TrkA protein observed during the transition from MCI to AD may signify the onset of neurotrophic signaling dysfunction that ultimately leads to the demise of these cholinergic neurons. We hypothesize that NB neuronal dysfunction is related to an imbalance between TrkA-mediated survival signaling and p75 NTR -mediated pro-apoptotic signaling. Elucidating the nature of proNGF signaling through these receptors will be critical for determining the physiologic consequences of cortical TrkA/p75 NTR receptor imbalances during the progression of AD. The use of NGF replacement therapy (127) in combination with TrkAselective agonists (132) may prove to be useful pharmacologic approaches for the treatment of cognitive loss due to degeneration of the cholinergic NB neurons in AD. Finally, if NGF is ''off-trk'' during the early stages of AD, then this phenomenon may be a novel diagnostic marker for the prodromal stages of AD. NTR is reduced in MCI and early stage AD. The frank loss of ChATpositive NB neurons is associated with late-stage AD. In contrast, cortical levels of TrkA protein are stable in MCI but reduced in AD, whereas p75 NTR levels in the cortex are stable throughout the disease progression. ProNGF protein levels increase during MCI and AD, whereas total levels of NGF are preserved. In addition to these cholinotrophic alterations, there is a de novo expression of cell cycle markers in NB neurons in MCI and early AD that may precede apoptotic signaling attributable to increased p75 NTR signaling. The lines do not represent actual numerical values but a general trend for each factor depicted.
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